1. Carter HB. Prostate Disorders: The Johns Hopkins White Papers. Baltimore, MD: Johns Hopkins Medicine. 2010:1-24.

2. Em 5 anos, apenas 4,4% dos pacientes precisaram posteriormente de outro procedimento cirúrgico para HBP e 11,1% de medicamentos para o controle dos sintomas de HBP após o tratamento com terapia com Rezūm™. McVary KT, Gittelman MC, Goldberg KA, et al. Final 5-year outcomes of the multicenter randomized sham-controlled trial of Rezūm water vapor thermal therapy for treatment of moderate-to-severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2021 Sep;206(3):715-24.

3. American Urological Association Education Research, Inc. American Urological Association Guideline: Management of Benign Prostatic Hyperplasia (BPH), Revised. 2010. Appendix 280, 283-5.

4. Barry M, Roehrborn C. Management of benign prostatic hyperplasia. Ann Rev Med. 1997 Feb; 48:177-89.

5. Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol. 1984 Sep;132(3):474-9.

6. McVary K: BPH: Epidemiology and Comorbidities. Am J Manag Care 12 2006; 5 Suppl: S122.

7. McVary KT, Rogers T, Roehrborn CG. Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. Urology. 2019 Apr; 126:171-9.

8. McVary KT, Gange SN, Gittelman MC, et al. Minimally invasive prostate convective water vapor energy (WAVE) ablation: A multicenter, randomized, controlled study for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2016 May;195(5):1529-38.

9. McVary KT, Roehrborn C. Five-year results of the prospective, randomized controlled trial of water vapor thermal therapy for treatment of lower urinary tractsymptoms due to benign prostatic hyperplasia. Late-Breaking Abstract. J Urol. 2020 Apr;203(4):e1021.

* Foi observada melhora significativa dos sintomas do trato urinário inferior e aumento de 45% na qualidade de a vida⁵.

** Depende da situação clínica individual e da resposta de recuperação.

*** Apenas 11,1% dos indivíduos tratado com Rezūm™ precisaram de medicação para HBP durante 5 anos.